日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

IQ Survey Results on Current Industry Practices: Part 2-Quantitative Evaluations of Immunogenicity Assessment

IQ调查结果：当前行业实践——第二部分：免疫原性评估的定量评价

期刊:Clinical Pharmacology & Therapeutics
影响因子:5.5
doi:10.1002/cpt.3573
Richards, Susan; Winzenborg, Insa; Luedtke, Doreen; Niu, Tao; Hamuro, Lora; Kowalski, Karey; Leu, Jocelyn H; Yang, Jianning; Ganti, Vaishnavi; Bhattacharya, Indranil; Gueorguieva, Ivelina; Mostafa, Nael; Grimaldi, Christine; Wu, Benjamin
免疫/内分泌
发表日期：2025
文献求助 收藏

Risankizumab: Mechanism of action, clinical and translational science

利沙珠单抗：作用机制、临床和转化科学

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.13706
Pang, Yinuo; D'Cunha, Ronilda; Winzenborg, Insa; Veldman, Geertruida; Pivorunas, Valerie; Wallace, Kori
发表日期：2024
文献求助 收藏

Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids

艾拉戈利克斯联合低剂量雌二醇/醋酸炔诺酮治疗子宫肌瘤女性患者的群体药代动力学

期刊:Clinical Pharmacokinetics
影响因子:4
doi:10.1007/s40262-021-01096-w
Beck, Denise; Winzenborg, Insa; Liu, Mohan; Degner, Jacob; Mostafa, Nael M; Noertersheuser, Peter; Shebley, Mohamad
发表日期：2022
文献求助 收藏

A Personalized Medicine Approach Using Clinical Utility Index and Exposure-Response Modeling Informed by Patient Preferences Data

基于患者偏好数据的临床效用指数和暴露-反应模型的个性化医疗方法

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.12570
Winzenborg, Insa; Soliman, Ahmed M; Shebley, Mohamad
发表日期：2021
文献求助 收藏

Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis

利用elagolix治疗子宫内膜异位症女性的3期临床试验数据验证钙稳态定量系统药理学模型

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.13040
Stodtmann, Sven; Nader, Ahmed; Polepally, Akshanth R; Suleiman, Ahmed A; Winzenborg, Insa; Noertersheuser, Peter; Ng, Juki; Mostafa, Nael M; Shebley, Mohamad
发表日期：2021
文献求助 收藏

Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid Arthritis

在II期和III期研究中对Upadacitinib的疗效和安全性进行暴露-反应分析，以支持类风湿性关节炎的获益-风险评估

期刊:Clinical Pharmacology & Therapeutics
影响因子:5.5
doi:10.1002/cpt.1671
Nader, Ahmed; Mohamed, Mohamed-Eslam F; Winzenborg, Insa; Doelger, Eva; Noertersheuser, Peter; Pangan, Aileen L; Othman, Ahmed A
关节炎
发表日期：2020
文献求助 收藏

Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis

Elagolix的临床药理学：一种用于治疗子宫内膜异位症的口服促性腺激素释放激素受体拮抗剂

期刊:Clinical Pharmacokinetics
影响因子:4
doi:10.1007/s40262-019-00840-7
Shebley, Mohamad; Polepally, Akshanth R; Nader, Ahmed; Ng, Juki W; Winzenborg, Insa; Klein, Cheri E; Noertersheuser, Peter; Gibbs, Megan A; Mostafa, Nael M
信号转导
免疫/内分泌
发表日期：2020
文献求助 收藏

Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis-Associated Pain: An Application of Markov Model

埃拉戈利克斯暴露对子宫内膜异位症相关疼痛女性患者III期临床试验疗效终点的影响：马尔可夫模型的应用

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.12545
Winzenborg, Insa; Polepally, Akshanth R; Nader, Ahmed; Mostafa, Nael M; Noertersheuser, Peter; Ng, Juki
发表日期：2020
文献求助 收藏

Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated Pain

暴露-安全性分析确定了骨矿物质密度变化的预测因子，并支持将Elagolix用于治疗子宫内膜异位症相关疼痛。

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.12560
Abbas Suleiman, Ahmed; Nader, Ahmed; Winzenborg, Insa; Beck, Denise; Polepally, Akshanth R; Ng, Juki; Noertersheuser, Peter; Mostafa, Nael M
发表日期：2020
文献求助 收藏